These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 25030442)

  • 1. Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia.
    Vrbacky F; Nekvindova J; Rezacova V; Simkovic M; Motyckova M; Belada D; Painuly U; Jiruchova Z; Maly J; Krejsek J; Zak P; Cervinka M; Smolej L
    Neoplasma; 2014; 61(5):585-92. PubMed ID: 25030442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features.
    Vrbacky F; Smolej L; Vroblova V; Pekova S; Hrudkova M; Cervinka M; Pecka M; Krejsek J; Maly J
    Hematology; 2010 Aug; 15(4):210-4. PubMed ID: 20670479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
    Wiestner A; Rosenwald A; Barry TS; Wright G; Davis RE; Henrickson SE; Zhao H; Ibbotson RE; Orchard JA; Davis Z; Stetler-Stevenson M; Raffeld M; Arthur DC; Marti GE; Wilson WH; Hamblin TJ; Oscier DG; Staudt LM
    Blood; 2003 Jun; 101(12):4944-51. PubMed ID: 12595313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZAP-70 mRNA quantification in B-cell chronic lymphocytic leukaemia.
    Catherwood MA; Matthews C; Niblock R; Dobbin E; Morris TC; Alexander HD
    Eur J Haematol; 2006 Apr; 76(4):294-8. PubMed ID: 16519700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lipoprotein lipase and serum thymidine kinase level in chronic lymphocytic leukemia and their correlations with other prognostic factors].
    Xu W; Shen QD; Yu H; Qiao C; Wu YJ; Liu Q; Zhu DX; Miao KR; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):8-12. PubMed ID: 19563027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
    Crespo M; Bosch F; Villamor N; Bellosillo B; Colomer D; Rozman M; Marcé S; López-Guillermo A; Campo E; Montserrat E
    N Engl J Med; 2003 May; 348(18):1764-75. PubMed ID: 12724482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
    Schade U; Bock O; Vornhusen S; Jäger A; Büsche G; Lehmann U; Kreipe H
    Hum Pathol; 2006 Sep; 37(9):1153-61. PubMed ID: 16938520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis.
    Martinelli S; Maffei R; Castelli I; Santachiara R; Zucchini P; Fontana M; Bonacorsi G; Leonardi G; Marasca R; Torelli G
    Leuk Res; 2008 Apr; 32(4):593-7. PubMed ID: 17928052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of selected markers of apoptosis and angiogenesis in chronic lymphocytic leukemia].
    Motyčková M; Smolej L; Andrýs C; Rezáčová V; Reháček V; Simkovič M; Belada D; Zák P
    Vnitr Lek; 2013 Sep; 59(9):782-93. PubMed ID: 24073950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
    Molica S; Digiesi G; Battaglia C; Cutrona G; Antenucci A; Molica M; Giannarelli D; Sperduti I; Gentile M; Morabito F; Ferrarini M
    Eur J Haematol; 2010 Oct; 85(4):314-20. PubMed ID: 20546021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers.
    Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P
    Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
    Terrin L; Trentin L; Degan M; Corradini I; Bertorelle R; Carli P; Maschio N; Bo MD; Noventa F; Gattei V; Semenzato G; De Rossi A
    Leukemia; 2007 May; 21(5):965-72. PubMed ID: 17344921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia.
    Francis S; Karanth M; Pratt G; Starczynski J; Hooper L; Fegan C; Pepper C; Valcarcel D; Milligan DW; Delgado J
    Cancer; 2006 Sep; 107(5):1023-33. PubMed ID: 16862572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
    Schroers R; Griesinger F; Trümper L; Haase D; Kulle B; Klein-Hitpass L; Sellmann L; Dührsen U; Dürig J
    Leukemia; 2005 May; 19(5):750-8. PubMed ID: 15759031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia.
    Smolej L; Andrys C; Peková S; Schwarz J; Belada D; Zák P
    Haematologica; 2006 Oct; 91(10):1432-3. PubMed ID: 17018398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997.
    Grever MR; Lucas DM; Dewald GW; Neuberg DS; Reed JC; Kitada S; Flinn IW; Tallman MS; Appelbaum FR; Larson RA; Paietta E; Jelinek DF; Gribben JG; Byrd JC
    J Clin Oncol; 2007 Mar; 25(7):799-804. PubMed ID: 17283363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenetics of chronic lymphocytic leukemia.
    Patkar N; Rabade N; Kadam PA; Mishra F; Muranjan A; Tembhare P; Chaudhary S; Joshi S; Jain H; Dangi U; Bagal B; Khattry N; Menon H; Gujral S; Sengar M; Subramanian PG
    Indian J Pathol Microbiol; 2017; 60(1):38-42. PubMed ID: 28195089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules.
    Kay NE; Bone ND; Tschumper RC; Howell KH; Geyer SM; Dewald GW; Hanson CA; Jelinek DF
    Leukemia; 2002 May; 16(5):911-9. PubMed ID: 11986954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients.
    Meuleman N; Stamatopoulos B; Dejeneffe M; El Housni H; Lagneaux L; Bron D
    Leukemia; 2008 Oct; 22(10):1882-90. PubMed ID: 18633433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia.
    Ferrer A; Ollila J; Tobin G; Nagy B; Thunberg U; Aalto Y; Vihinen M; Vilpo J; Rosenquist R; Knuutila S
    Cancer Genet Cytogenet; 2004 Aug; 153(1):69-72. PubMed ID: 15325098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.